RxDoctor Payments DataLook up a doctor →

Susan Ogden, APRN

Family · Oklahoma City, OKNPI 1316317688

Payments from drug & device makers

$9,966in general payments, 2019–2025

Across 572 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • AstraZeneca$1K
  • AbbVie$946
  • Otsuka America Pharmaceutical, Inc.$603
  • Lilly USA, LLC$571
  • Lundbeck LLC$500
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$9,89899%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,966 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$50,935
Medicare patients
219
Services billed
1,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$90,617
MounjaroTirzepatide37$74,999
JardianceEmpagliflozin19$32,738
EliquisApixaban25$23,956
LinzessLinaclotide29$23,500
FarxigaDapagliflozin Propanediol21$20,872
XareltoRivaroxaban11$14,862
GemtesaVibegron17$12,474
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$12,247
VascepaIcosapent Ethyl19$9,946
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,212
SymbicortBudesonide/Formoterol Fumarate11$2,798
Atorvastatin Calcium135$1,801
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,487
Aripiprazole11$1,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$62$90,61748 claims
Lilly USA, LLCMounjaro$571$74,99937 claims
Boehringer IngelheimJardiance$300$32,73819 claims
PfizerEliquis$225$23,95625 claims
AstraZenecaFarxiga, Symbicort$1,149$23,67032 claims
AbbVieLinzess$946$23,50029 claims
Johnson & JohnsonXarelto$13$14,86211 claims
Sumitomo Pharma America, Inc.Gemtesa$45$12,47417 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,226160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.

Other family in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →